HIGHLIGHTS
- who: Michael J. Coyne et al. from the Toxicology Division, Lilly Research Laboratories, Eli Lilly and Company, Indianapolis, Indiana, United States have published the Article: Evaluation of renal injury and function biomarkers, including symmetric dimethylarginine (SDMA), in the rat passive Heymann nephritis (PHN) model, in the Journal: PLOS ONE of February/23,/2022
- what: The aim of this study was to determine the performance of serum SDMA in a rat passive Heyman nephritis model of glomerulopathy. The urinary biomarkers measured in this study have been previously qualified by the FDA for assessment of renal toxicity . . .
If you want to have access to all the content you need to log in!
Thanks :)
If you don't have an account, you can create one here.